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Neurosteroids were initially deﬁned as steroid hormones locally synthesized within the
nervous tissue. Subsequently, they were described as steroid hormone derivatives that
devoid hormonal action but still affect neuronal excitability throughmodulation of ionotropic
receptors. Neurosteroids are further subdivided into natural (produced in the brain) and syn-
thetic. Some authors distinguish between hormonal and regular neurosteroids in the group
of natural ones. The latter group, including hormone metabolites like allopregnanolone or
tetrahydrodeoxycorticosterone, is devoid of hormonal activity. Both hormones and their
derivatives share, however, most of the physiological functions. It is usually very difﬁcult
to distinguish the effects of hormones and their metabolites. All these substances may
inﬂuence seizure phenomena and exhibit neuroprotective effects. Neuroprotection offered
by steroid hormones may be realized in both genomic and non-genomic mechanisms and
involve regulation of the pro- and anti-apoptotic factors expression, intracellular signaling
pathways, neurotransmission, oxidative, and inﬂammatory processes. Since regular neu-
rosteroids show no afﬁnity for steroid receptors, they may act only in a non-genomic mode.
Multiple studies have been conducted so far to show efﬁcacy of neurosteroids in the treat-
ment of the central and peripheral nervous system injury, ischemia, neurodegenerative
diseases, or seizures. In this review we focused primarily on neurosteroid mechanisms
of action and their role in the process of neurodegeneration. Most of the data refers to
results obtained in experimental studies. However, it should be realized that knowledge
about neuroactive steroids remains still incomplete and requires conﬁrmation in clinical
conditions.
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INTRODUCTION
In the century of spectacular medical therapies, there is still a
lack of substance that may protect the brain cells against neurode-
generation. Since the discovery of neurosteroids, scientists have
made a great effort to evaluate their function, including possible
neuroprotective properties. According to most commonly used
deﬁnition neurosteroids cover both steroid hormones, which are
synthesizedde novo in neurons and glial cells, and theirmetabolites
actingwithin the central nervous system(CNS) (Compagnone and
Mellon, 2000) (Figure 1). Hormones may regulate brain function
in an autocrine and paracrine manner via membrane or nuclear
receptors (Baulieu, 1998; Baulieu et al., 2001; Plassart-Schiess and
Baulieu, 2001; Singh, 2006). Regular neurosteroids act as positive
or negative modulators of neurotransmitter receptors: gamma-
amino butyric acid A (GABAA) receptor, N -methyl-d-aspartate
(NMDA) receptor, α-amino-3-hydroxy-5-methylisoxazole pro-
pionate (AMPA) receptor, sigma-1 (σ1), nicotinic, muscarinic,
kainic, serotoninergic and glycine receptors, regulate gene expres-
sion, or signaling cascades (Wojtal et al., 2006; Borowicz et al.,
2008). In this article we review the main neurosteroids, including
pregnenolone (PREG) and pregnenolone sulfate (PREGS), prog-
esterone (PROG), allopregnanolone (ALLO), dehydroepiandros-
terone (DHEA), DHEA sulfate (DHEAS), deoxycorticosterone
(DOC), and tetrahydrodeoxycorticosterone (THDOC).
From the biochemical point of view, PREG is a hormone pre-
cursor, PROG,DOC, and DHEA represent hormones,while ALLO
(a PROG metabolite) and THDOC (a DOC derivative) belong
to neurosteroids, which are entirely devoid of hormonal action.
However, their ketone metabolites may activate hormonal recep-
tors. An additional advantage of regular neurosteroids is better
bioavailability and longer half-life. Synthetic neurosteroids have
even longer half-time, and may be administered orally, in con-
trast to natural steroids (Wojtal et al., 2006; Borowicz et al.,
2008).
Neuroprotection involves mechanisms protecting against neu-
ronal injury or degeneration in the central and peripheral nervous
system.All these processesmaybe a consequence of acute disorders
(e.g., stroke or nervous system injury) or chronic neurodegenera-
tive processes (e.g., in the course of Alzheimer’s, Parkinson’s, and
Huntington’s disease). The overriding aim is, of course, to pre-
vent the development of a disease, but it is equally important to
limit neuronal dysfunction after the CNS injury and maintain
undisturbed neural function of the brain with the highest possi-
ble cellular integrity. At present, a wide range of neuroprotective
products is available or under investigation. Many of them can
potentially be used in more than one disorder, because most of the
underlying mechanisms of neurodegeneration (in both acute and
chronic disorders) seems to be quite similar.
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Until recently two mechanisms of cell death were known: the
programmed cell death (apoptosis) and unregulated process of
necrosis. Necrosis and apoptosis differ with numerous morpho-
logical and biochemical features. In necrosis, extreme physio-
logical conditions (e.g., hypoxia) lead to damage to the plasma
membrane. The whole cell and intracellular organelles, partic-
ularly mitochondria, swell, and rapture. As a consequence of
loss of membrane integrity, the cytoplasmic contents, including
lysosomal enzymes, are released into the extracellular ﬂuid. This
process ends with cell lysis and is often associated with a vast
tissue damage resulting from an intense inﬂammatory response
(Majno and Joris, 1995; Kanduc et al., 2002; Van Cruchten and
Van Den Broeck, 2002). Nevertheless, it has been proved that non-
apoptotic forms of programmed cell death may also exist. In fact,
threemain types of the programmeddeath has been distinguished:
1. nuclear (apoptotic); 2. autophagic (lysosomal); and 3. cytoplas-
mic. Autophagic cell death can be activated by Ras genes, while
type 3 (cytoplasmic) was shown to be triggered by stimulation of
the insulin-like growth factor I receptor (IGFIR) or the binding of
substance P to its neurokinin-1. This form, characterized by cyto-
plasmic vacuolization, lack of apoptotic morphology, and lack of
caspase activation, was named paraptosis (Sperandio et al., 2000,
2004, 2010; Leist and Jäättelä, 2001; Yakovlev and Faden, 2004;
Kroemer et al., 2009).
However, accumulating evidences indicate that necrotic cell
death can also be a regulated process. In 2005 the term necroptosis
was introduced to describe a little known yet alternative form of
cell death – the programmed necrosis (Teng et al., 2005; Vanden-
abeele et al., 2010). Necroptosis is deﬁned as a programmed but
caspase-independent cell death that activates autophagy and mor-
phologically resembles necrosis (Degterev et al., 2005; Teng et al.,
2005). Whether this form of cell death should be equated with the
programmed autophagic form remains uncertain. This process, in
fact intermediate between necrosis and apoptosis, develops often
as an answer to hypoxia, reperfusion, and excitotoxicity. These
ﬁndings open a possibility to develop new therapeutic strategies
that may extend the window for neuroprotection in such disorders
as stroke, trauma and neurodegenerative diseases. Interestingly,
necrostatin-1 and 5, lately identiﬁed speciﬁc and potent small-
molecule inhibitors of necroptosis, were shown to block a critical
FIGURE 1 | Schematic synthesis of neurosteroids in the CNS.
stepof the cell deathprocess (Yuan et al., 2003;Degterev et al., 2005;
Mehta et al., 2007;Wang et al., 2007). In fact, research on neuronal
death mechanisms may help to develop an effective neuropro-
tective treatment and contribute to a signiﬁcant improvement in
patient quality of life (Charalampopoulos et al., 2008).
PREGNENOLONE
Pregnenolone, usually considered as a neurosteroid precursor,
exhibited neuroprotective effects against glutamate- and amyloid
β protein-induced neurotoxicity in clonal mouse hippocampal
cell line (HT-22; Gursoy et al., 2001). It also stabilized micro-
tubules (Hsu et al., 2006), enhanced its polymerization and
activated neurite outgrowth in nerve growth factor-pretreated
clonal rat pheochromocytoma cell line of neuronal crest ori-
gin, PC12 (Fontaine-Lenoir et al., 2006), improves myelination
(Koenig et al., 1995). According to Leskiewicz et al. (2008) PREG
reduced the staurosporine- and glutamate-induced LDH release
and diminished the number of apoptotic cells in primary neu-
ronal cortical cultures. Additionally, PREG exerted neuroprotec-
tive effects against kainate-induced cell death in the hippocampus
of gonadectomized rats. The exact mechanism of PREG action
is not clear, however, it may be mediated by estradiol, the main
product of aromatase action. Fadrozole, an aromatase inhibitor,
prevented the neuroprotective effects of both neurosteroids (Veiga
et al., 2003). In patientswithAlzheimer’s disease,PREGconcentra-
tions were reduced in the striatum and cerebellum. Interestingly,
the negative correlation was shown between PREG and the level of
corticalβ-amyloid (Weill-Engerer et al., 2002; Luchetti et al., 2011).
In rat hippocampal slices, PREG inhibited, or enhanced NMDA
response. The former effect appeared in the presence of haloperi-
dol and indicates an indirect σ receptor modulation. The latter
one seems to be dependent on a direct NMDA receptor response
(Monnet et al., 1995) (Table 1).
PROGESTERONE AND DERIVATIVES
Progesterone is produced primarily in females in the ovarian cor-
pus luteum and placenta, while in males it is mostly found in testes
and adrenal glands. However, this hormone may also be synthe-
sized de novo within the nervous system. Initially, it was observed
that brain concentrations of PROG maintained even in gonadec-
tomized rats (Corpéchot et al., 1983). Then, glial cell cultures
were reported to synthesize PROG and express PROG receptors
Table 1 | Leading actions of chosen neurosteroids.
Neurosteroid Seizures Excitotoxicity ND TBI IBI
PREG + +
PROG + + + +




PREG, pregnenolone; PROG, progesterone; ALLO, allopregnanolone; DHEA,
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate ester; DOC,
deoxycorticosterone; THDOC, allotetrahydrodeoxycorticosterone.
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(Jung-Testas et al., 1989, 1999). The hormone and its derivatives
are positive modulators of GABAA receptors (Borowicz et al.,
2008). PROG is synthesized in human brain at the similar level
in both sexes (Stein and Wright, 2010). Identiﬁcation of neuro-
protective properties of this steroid began with the observation
of a better recovery of female pseudopregnant rats after the trau-
matic brain injury (TBI; Roof et al., 1993). The authors observed
the inverse correlation between serum PROG concentration and
degree of brain edema after injury (Wright et al., 2001). In male
and normal cycling female rats, administration of PROG (in the
1st, 6th, 24th, and 48th h after TBI) signiﬁcantly protected animals
against the development of brain edema and cognitive impair-
ment (Roof et al., 1996; Stein, 2001; Wright et al., 2001). It could
be concluded that the positive effect of PROG treatment could be
achieved when the steroid is administered within 24 h after injury,
although the sooner onset of the treatment means the better out-
come. The optimal dose of PROG ranged from 8 to 16mg/kg
(Roof et al., 1996; Stein, 2008). Furthermore, Shear et al. (2002)
tested 3- and 5-days regimen of PROG administration after TBI
and observed a signiﬁcant reduction size of injury-induced necro-
sis and diminished cell loss in the dorsomedial nucleus of the
thalamus. The latter process facilitated behavioral recovery of ani-
mals. PROG, used at low physiological doses in ovariectomized
female rats after TBI, reduced alterations in mitochondrial res-
piration and hippocampal cell loss (Robertson et al., 2006). In
another study, treatment with PROG following TBI diminished
production of inﬂammatory proteins in rats (Pettus et al., 2005).
Roof et al. (1997) conﬁrmed antioxidant effect of PROG. This hor-
mone administered after a TBI episode signiﬁcantly lowered the
brain concentration of isoprostaglandin, an established marker of
lipid peroxidation.
Advantageous properties of PROG were also observed in mod-
els of the spinal cord and peripheral nerve injury. The hormone
administered for 3 days following the spinal cord injury improved
myelination, increased the level of brain derived neurotrophic
factor (BDNF) mRNA and reduced chromatolysis (De Nicola
et al., 2006), whereas 5-day administration diminished the size
of lesions and prevented secondary neuronal loss (Thomas et al.,
1999). According to Labombarda et al. (2010) PROG signiﬁcantly
enhanced BDNF neuronal expression, up-regulated growth-
associated protein 43 (GAP-43) necessary for axonal regeneration,
prevented the injury-induced chromatolytic changes of spinal
neurons and increased activity of enzymes crucial for normal neu-
ronal metabolism and neurotransmission, and restored impaired
expression of the Na,K-ATPase subunits and choline acetyltrans-
ferase. On the other hand, Coughlan et al. (2009) found no evi-
dence for neuroprotective relationship between BDNF and PROG.
Administration of PROG following acute spinal cord injury in rats
attenuated the loss of microtubule-associated protein 2, a major
component of the cytoskeleton (González et al., 2009). In addi-
tion, this steroid acts as a promyelinating factor by stimulating
synthesis of myelin proteins and proliferation/differentiation of
oligodendrocyte progenitors (Gonzalez et al., 2005; Labombarda
et al., 2010).
Yu (1989) observed that PROG treatment followingmotor neu-
ron axotomy attenuated loss of neurons in rats. According to
Koenig et al. (1995) PROG induced myelin repair after cryolesion
of peripheral nerves in mice. The same hormone increased expres-
sion of genes coding crucial myelin proteins in rat Schwann cells
(Désarnaud et al., 1998). In rat peripheral nerves PROG increased
glial cell growth and differentiation, induced synthesis of myelin-
speciﬁc proteins in oligodendrocytes, and potentiated the forma-
tion of new myelin sheaths by Schwann cells (Jung-Testas et al.,
1999; Baulieu and Schumacher, 2000).
Progesterone administration following the cortical contusion
injury protected against secondary neuronal loss and facilitated
cognitive recovery in rats (Roof et al., 1994; Asbury et al.,
1998). In the diffused TBI model, administration of physiolog-
ical doses of PROG reduced cell loss, axonal injury, decreased
caspase-3 immunoreactivity, and facilitated the motor and cogni-
tive performance recovery in male and ovariectomized female rats
(O’Connor et al., 2007). In themodel of ischemic injury, treatment
with PROG reduced brain cell damage, improved neurological
outcome in rats (Jiang et al., 1996; Chen et al., 1999; Kumon et al.,
2000), and increased survival rate in mice (Gibson and Murphy,
2004). In the studyof Jiang et al. (1996) the effectswere comparable
eitherwhen the hormonewas given immediately before or 2 h after
reperfusion. Post-injury administration of PROG in rats with the
brain global ischemia resulted in a signiﬁcant reduction of cortical
shrinkage and cell loss in the CA1 and CA2 hippocampal sub-
ﬁelds. Additionally, the hormone prevented ventricular dilatation
compared with control animals (Moralí et al., 2005). In another
study, application of PROG and ALLO after severe transient fore-
brain ischemia in rats resulted in better functional outcome and
preserved dimensions of hippocampal formation despite pyrami-
dal neurons loss (Moralí et al., 2011). Similarly, in cats after acute
global ischemia PROG reduced cell loss, especially in the CA1/CA2
areas, and caudate nucleus regions (González-Vidal et al., 1998;
Cervantes et al., 2002). In permanent middle cerebral artery occlu-
sion model in rats, this steroid diminished cortical and optionally
subcortical infarct volumes (Alkayed et al., 2000). Both PROG and
ALLO improved behavioral outcome of animals (Sayeed et al.,
2007). Recently, Cai et al. (2008) found that acute neuroprotective
effects of PROG in ischemic brain injury may depend on its antag-
onistic action toward the σ1 receptor and subsequent inhibition
of the NMDA-induced Ca inﬂux. Finally, PROG was investigated
in the ProTECT clinical study. It was observed that patients with
acute TBI, treated with PROG, had a lower 30-day mortality rate
than control individuals (Wright et al., 2006). Similarly, lowermor-
tality and better functional outcomes were found in the PROG
groupof patients byXiao et al. (2008) and Stein andWright (2010).
At least two third-phase clinical trials are currently run to conﬁrm
neuroprotective properties of this hormone in patients after brain
injury (Stein and Wright, 2010).
Neuroprotective effects of PROG were also shown in ani-
mal models of spinal cord degeneration. Wobbler mice receiving
the hormon presented less pronounced neuropathology, reduced
number of vacuolated cells, preserved mitochondrial ultrastruc-
ture (Gonzalez Deniselle et al., 2002), attenuated motoneuron
degeneration and boosted myelination in Schwann cells and oligo-
dendrocytes in the CNS (Schumacher et al., 2004). According to
Martini et al. (2003) PROG and its derivatives: dihydroproges-
terone (DHP) and tetrahydroprogesterone (THP) may control the
expression of the glycoprotein Po peripheral myelin and protein
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22 (PMP22) via activation of the PROG receptor orGABAA recep-
tor, respectively. Neuroprotective properties of PROG and its two
metabolites were shown by Leonelli et al. (2007) in streptozotocin-
induced diabetic neuropathy model in rats. Chronic (1month
lasting) treatment with these neurosteroids preserved the nerve
conduction velocity, thermal threshold, intra-epidermal nerve
ﬁber density, Na(+)K(+)-ATPase activity, and mRNA levels of
myelin proteins (Leonelli et al., 2007).
Neuroprotective action of PROG seem to be partially due to
reduction of cerebral edema that may be achieved via different
mechanisms: protecting or rebuilding the blood–brain barrier
(Duvdevani et al., 1995; Roof et al., 1997), modulating aquapor-
ins (Amiry-Moghaddam et al., 2003), up-regulation of membrane
PROG binding protein 25-Dx, which is co-expressed with vaso-
pressin and regulates brain water homeostasis, and reduction of
the cytotoxic phase of edema (Guennoun et al., 2008; Stein et al.,
2008). Other possible actions of PROG include: down-regulation
of the inﬂammatory cascade by decelerating cytokine (IL-1; IL-
6; TNFα)-induced reactions, slowing the immune cell activation,
and migration (Arvin et al., 1996; Grossman et al., 2004; Stein,
2008). This neurosteroid limits cellular necrosis and apoptosis by:
1. lowering the concentration of nuclear factor κβ and expres-
sion of its target genes such as IL-1β, C3, iNOS, COX2 (Pettus
et al., 2005; Stein, 2008), 2. reducing excitotoxicity by inhibition of
glutamate receptors, 3. boosting the effects of GABAA, 4 depres-
sion of spontaneous ﬁring of neurons, a possible causative factor
of posttraumatic seizures (Bergeron et al., 1996; Pierson et al.,
2005; Stein, 2008), 5. stimulation of Schwann’s cells via nuclear
receptor to produce myelin, and reducing glial scarring in the
CNS (Koenig et al., 1995; Plassart-Schiess and Baulieu, 2001), 6.
decreasing injury-induced lipid peroxidation and oxidative stress
via inhibition of TNF-α production or up-regulation of antiox-
idant enzymes (Roof et al., 1997; Stein, 2008; Stein and Wright,
2010).
Progesterone activates signaling pathways associated with neu-
roprotection like mitogen activated protein kinase, extracellu-
lar signal regulated kinase (MAPK/ERK), or serine/threonine
protein kinase Akt (Brinton et al., 2008). Nilsen and Brinton
(2002) showed that PROG increased expression of the Bcl-2 anti-
apoptotic gene, which prevented cell death in rat hippocampal
neuronal cultures. In the TBI model in rats, administration of
PROG increased mRNA levels of the Bcl-2 and Bcl-x(L) anti-
apoptotic genes, and their protein derivatives. On the contrary,
the hormone reduced mRNA levels of pro-apoptotic bax and
bad genes, as well as their protein products (Yao et al., 2005).
Additionally, the neurosteroid attenuates release of the proapop-
totic cytochrome c (Stein and Wright, 2010). In cultured hip-
pocampal neurons, PROG attenuated lipid peroxidation induced
by FeSO4 and amyloid β-peptide, as well as lightened eleva-
tion of intracellular Ca2+ concentration following β-amyloid- or
glutamate-induced toxicity (Goodman et al., 1996).
In rats after TBI, administration of ALLO decreased apoptotic
DNA fragmentation and expression of caspase-3 and Bax pro-
apoptotic proteins. Moreover, the neurosteroid improved behav-
ioral outcome of animals similarly to PROG (Djebaili et al.,
2004, 2005). ALLO and PROG protected the rat brain from
post-injury edema. Both neurosteroids reduced production of
pro-inﬂammatory cytokines (IL-1, TNF-α; He et al., 2004) and
enhanced production of the CD55 protein, a complement conver-
tase inhibitor, which was reported to limit inﬂammatory processes
after contusion of the cerebral cortex in rats (VanLandingham
et al., 2007). In patients with Alzheimer’s disease, the level of
ALLO in the temporal cortex was signiﬁcantly lower than in con-
trols, in contrast to PREG and DHEA which concentrations were
increased. This may be explained by altered regulation of neuros-
teroid biosynthetic pathway, blocking ALLO formation (Naylor
et al., 2010). Similarly, the ALLO level was found to be decreased
in Niemann-Pick type. The neurosteroid administration doubled
the animal lifespan and delayed the onset of neurological symp-
toms. Furthermore, ALLO enhanced myelination and reduced
inﬂammatory processes in brains of Npc1(−/−) mice, a genetic
model of Niemann-Pick type C disease (Grifﬁn et al., 2004;
Ahmad et al., 2005; Mellon et al., 2008; Liao et al., 2009). Callier
et al. (2001) revealed that PROG protected dopaminergic neurons
against MPTP-induced degeneration in rats. Moreover, in MPTP
mice, PROG did not reverse the protective effect of estrogens on
dopamine neurons. In methamphetamine model of Parkinson’s
disease, PROG used at low doses exerted protective action on stri-
atal dopaminergic neurons in gonadectomizedmalemice,whereas
much higher doses were needed to achieve a beneﬁcial effect in
ovariectomized mice (Bourque et al., 2009).
Higher concentrations of PROG, ALLO, and 5α-DHP were
found in the substantia nigra and nucleus caudate in compari-
son with other brain areas in female control patients. In patients
with Parkinson’s disease, lower concentrations of these neuros-
teroids than in controls were found in the cerebrospinal ﬂuid (CSF;
Luchetti et al., 2011). During further studies the authors observed
reduced mRNA expression of one enzyme synthesizing ALLO in
the substantia nigra, and increased expression of another one in
the caudate nucleus. It seems that disturbed synthesis of ALLO
may result in a dysfunction of endogenous neuroprotective effects
(Luchetti et al., 2011). Similarly, diminished ALLO concentration
and reduced activity of enzymes synthesizing the neurosteroid
were found in patients with multiple sclerosis (Luchetti et al.,
2011). Such phenomenon as NMDA-induced excitotoxicity in P-
19 cell cultures (pluripotent embryonic cells differentiated into
neurons) was attenuated by ALLO and DHEA, while DHEAS
remained less effective in this respect. ALLO prevented the release
of cytochrome c to cytoplasm and Bax protein translocation to
mitochondria. All these processes are considered to be signs of
apoptotic death. Since both neurosteroids enhanced expression of
GABAA receptor subunits, their neuroprotective action seems to
bemediated by enhancedGABA-ergic neurotransmission (Xilouri
and Papazaﬁri, 2006).
Allopregnanolone appears to play a signiﬁcant role in the
pathogenesis of Alzheimer’s disease. Reduced levels of this steroid
were found in the patient plasma and prefrontal cortex. Addition-
ally, elevated concentrations of enzymes metabolizing pregnane
steroids were found in brains from early stages of the disease
(Luchetti et al., 2011). In the mouse model of Alzheimer’s dis-
ease PROG treatment improved cognitive functions and reduced
hyperphosphorylation of tau protein. But on the other hand,
PROG antagonized beneﬁcial effects of estrogens in reducing β-
amyloid deposits. It is possible that the sequential therapy with
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estrogen and PROG may bring better results than the treatment
with only one hormone (Pike et al., 2009).
Allopregnanolone prevented apoptotic cell death in the human
NT2 cell line culture in NMDA-induced excitotoxicity (Lockhart
et al., 2002).
Progesterone is widely considered as a pleiotropic drug that
can be markedly effective in the treatment of TBI. At present,
more than 180 articles showed protective activity of PROG in both
experimental animals and humans. Moreover, two independent
phase II clinical trials have revealed that PROG group of patients
had signiﬁcantly better survival and functional outcomes than
patients given placebo. Currently, phase III clinical trial is con-
ducted in the United States. Nevertheless, in some studies PROG
was not effective or even worsen the prognosis of animals after
TBI or ischemic injury (Murphy et al., 2000; Toung et al., 2004;
Ciriza et al., 2006; Gilmer et al., 2008; Stein, 2008, 2011; Stein
and Wright, 2010). The probable reason of PROG treatment fail-
ure may be advanced age of used animals. Anyway, PROG proved
efﬁcacy and safety in most models of TBI. Surprisingly, medrox-
yprogesterone acetate, a PROG synthetic derivative, may exhibit
quite opposite properties in the CNS than the parent compound.
Medroxyprogesterone did not bring better functional outcome
after TBI, moreover, it blocked the expression of Bcl-2 gene and
estrogen-dependent neuroprotection, increased calcium-induced
toxicity (Stein, 2008).
Anticonvulsive and antiexcitotoxic properties of PROG were
widely examined in animal models and clinical studies. It seems
that antiseizure action of this hormone is not mediated by steroid
receptor since it occurs quickly (withinminutes) and is not blocked
by the respective receptor antagonist – RU486. GABAA recep-
tor activation induces neuronal membrane hyperpolarization and
reduces its excitability.
In kainic acid-induced seizures in rats the hormone sig-
niﬁcantly reduced seizures, mortality, and neuronal death in
hippocampus (Hoffman et al., 2003). In the same model in mice,
ALLO protected against seizures and reduced neuronal loss in hip-
pocampal ﬁelds, while other neurosteroids – negative modulators
of GABAA receptor (DHEAS, PREGS) – remained ineffective or
even toxic (Leskiewicz et al., 1997). Holmes and Weber (1984)
tested PROG in amygdala-kindled rats and observed kindling
inhibition. Secondary generalization of seizures was prevented
in immature, but not adult animals. In the same model, PROG
and ALLO protected against secondarily generalized seizures,
being ineffective or effective only at toxic doses against focal
seizures. On the other hand, 5α-DHP inhibited both components
of seizures (Lonsdale et al., 2006). Growing evidence suggests
that anticonvulsive and neuroprotective properties of PROG are
mediated by its metabolites 5α-DHP and ALLO, positive mod-
ulators of GABAA receptors (Reddy, 2004; Ciriza et al., 2006;
Verrotti et al., 2010; Stevens and Harden, 2011). ALLO itself pro-
tected against picrotoxin-induced neuronal cell death (Brinton,
1994). Rhodes and Frye (2005) showed that inhibition of 5α-
reductase enzyme (ﬁnasteride) attenuated antiseizure activity of
PROG and reduced concentration of ALLO. However, according
to Leskiewicz et al. (2003) ALLO showed no signiﬁcant anticon-
vulsive action against cocaine-induced kindling in mice, in con-
trast to isopregnanolon and a representative of negative GABAA
modulators – DHEAS. The authors suggest that antiseizure prop-
ertiesmaynot depend exclusively onGABAA receptormodulation.
Some other neurosteroids were reported to inhibit seizures.
Both PROG derivatives: DHP and ALLO dose-dependently
protected the kainate-induced loss of hilar neurons and the induc-
tion of vimentin expression in reactive astrocytes (a sign of neural
damage) in ovariectomized rats (Ciriza et al., 2004) (Table 1).
DEHYDROEPIANDROSTERONE AND
DEHYDROEPIANDROSTERONE SULFATE ESTER
Dehydroepiandrosterone and its sulfate ester (DHEAS) were
reported to act as neurotropic or neuroprotective factors, defend-
ing neurons against many harmful events, including excitotoxicity.
Protective properties of DHEA may be related to inhibition of the
NMDA-induced nitric oxide (NO) production in hippocampal
cells or modulation of the calcium/NO signaling pathway. The
action of this hormone can be also mediated by sigma recep-
tors. Additionally, DHEAS was shown to attenuate the destructive
action of glutamate and NMDA on cerebellar granule cells in
rats. Protective effects of both DHEA and DHEAS can be realized
through preventing the mitochondria against intracellular Ca2+
overload (Mao and Barger, 1998). Time- and dose-dependent
neuroprotective action of DHEA was documented in the in vivo
model of global cerebral ischemia in rats.Administrationof DHEA
at the dose of 20mg/kg during 3–48 h after ischemia reduced
neuronal death in the hippocampal CA1 region and ameliorated
ischemia-induced deﬁcits in spatial learning. Whereas, the treat-
ment of DHEA (20mg/kg, 1 h before or after ischemia) may inten-
sify the ischemia-induced neuronal damage and learning failure.
Moreover, treatment with doses 25–100mg/kg (for 15 days before
induction of ischemia) led to more pronounced neuroprotective
effects and reduced hippocampal CA1 neuronal injury (Li et al.,
2001). These study may suggest that DHEA, dependently on time
of treatment, exhibits a dual action – it may be either neurotoxic
or neuroprotective, depending on the time of treatment initiation
and duration (Li et al., 2009).
DHEA sulfate signiﬁcantly inhibited the amplitude of persis-
tent sodiumcurrents, and this result was canceled by theGi protein
inhibitor, protein kinase C inhibitor, sigma-1 receptor blockers,
but not by the protein kinase A inhibitor. These results suggest
that DHEAS may protect neurons against ischemia by activation
of sigma-1 receptor (Cheng et al., 2008). DHEAS has been also
investigated in the reversible spinal cord ischemia model. The neu-
rosteroid exhibited a preventive effect when it was administered
5min,but not 30min after ischemia. Thebeneﬁcial effect of DHEA
was reversed by bicuculline, the GABAA antagonist, which indi-
cates GABA-ergic mechanism of the neurosteroid action (Lapchak
et al., 2000).Aforementioned results show thatDHEA andDHEAS
may provide neuroprotection against ischemia. However, it should
be remembered that DHEA administered during ischemia may be
also neurotoxic.
According Kimonides et al. (1998), DHEA showed a dose-
dependent neuroprotective effect against glutamate excitotoxicity
mediated by NMDA receptors (in vivo and in vitro) or evoked
by AMPA/KA receptor agonists (in vitro). For instance, the neu-
rosteroid prevented hippocampal CA1/2 neurons against toxicity
induced by NMDA infusions. Thus, decreased level of DHEA
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in aging people may increase vulnerability of the brain to such
a damage. Age-related declines of neurosteroids have been pos-
tulated to play a role in the pathogenesis of neurodegenerative
diseases (Hillen et al., 2000; Brown et al., 2003; Naylor et al., 2008).
Interestingly,DHEA-induced protection against KA-induced exci-
totoxicity in hippocampal hilar neurons was attenuated by letro-
zole, an aromatase inhibitor (Veiga et al., 2003). Taking this
into consideration, neuroprotective effects of DHEA in the hip-
pocampus can be mediated by estradiol (Azcoitia et al., 1998;
Garcia-Segura et al., 2003). It should be stressed that expression
of aromatase in reactive glial cells is induced after brain injury
(Garcia-Segura et al., 2003).
Some results suggest that DHEAS may be a negative modulator
of GABAA receptors. In the study of Czlonkowska et al. (2000),
intracerebroventricularly administered DHEAS induced seizures
in a dose-dependent manner. But on the other hand, DHEAS
(25mg/kg, i.p.) signiﬁcantly increased the dose of NMDA nec-
essary to induce clonic convulsions in mice, indicating that the
neurosteroids can protect mice against NMDA-induced seizures
and mortality (Budziszewska et al., 1998). The antiseizure effect
of DHEA was also proved in the iron-induced model of post-
traumatic epilepsy in rats. DHEA at the dose of 30mg/kg/day
prevented epileptiform electrophysiological activity and attenu-
ated cognitive defects produced by epileptic activity (Mishra et al.,
2010). It is worth mentioning that neurosteroids may serve as
regulators of epileptogenesis. This raises the possibility that exoge-
nously administered neurosteroids or their synthetic analogs could
be clinically effective as antiepileptogenic drugs, e.g., after TBI
(Biagini et al., 2006). In the study of Fiore et al. (2004), DHEA
provided better locomotor recovery, left–right coordination, and
ﬁne motor control in mice after contusive spinal cord injury. Pos-
sibly, these drugs may create a promising novel therapeutic avenue
for the treatment of this dysfunction in humans. Further, DHEA
was reported to reduce the extent of denervation atrophy. The
neurosteroid accelerated axonal regeneration (Ayhan et al., 2003)
and increased the number of myelinated ﬁbers and ﬁber diameters
after sciatic nerve transection in rats (Gudemez et al., 2002).
According to Frye and Reed (1998), a 3α-Diol metabolite of
another androgen – testosterone – exhibited anticonvulsive effect
against seizures induced in rats by kainate or perforant pathway
stimulation.Moreover, the neurosteroid reduced hippocampal cell
death and improved animal performance in the Morris water
maze. Interestingly, this action was inhibited by GABAA receptor
blockade, therefore it is not clear whether the action of 3α-Diol is
due to enhanced GABA-ergic neurotransmission or to increased
estrogen concentration (Table 1).
DEOXYCORTICOSTERONE AND
ALLOTETRAHYDRODEOXYCORTICOSTERONE
Although there is no literature data on neuroprotective prop-
erties of deoxycorticosterone DOC) and its derivative allote-
trahydrodeoxycorticosterone (THDOC), the two neurosteroids
exhibited anticonvulsive effects in some experimental studies. For
instance, THDOC protected against convulsions induced by the
GABAA receptor antagonists, like picrotoxin, pentylenetetrazole,
or bicuculline, and the glutamate receptor agonists, such as kainic
acid or NMDA. The neurosteroid, administered at relatively high
doses, showed also the anticonvulsive action in the rat model of
amygdala kindling and the maximal electroshock test in mice. In
human studies, decreased serum level of THDOC was found in
women with catamenial epilepsy, which may indicate a role of this
neurosteroid in the pathophysiology of perimenstrual seizures.
The antiseizure effect of THDOC seems to depend on positive
allosteric modulation of GABAA receptor (Reddy, 2009) (Table 1).
SYNTHETIC NEUROSTEROIDS
The main disadvantage of natural neurosteroids is their short bio-
logical half-life. Therefore some modiﬁed derivatives were synthe-
sized in order to select drugs,which are not so rapidlymetabolized.
Neurosteroid analogs offered mainly a broad spectrum of
anticonvulsive activity in different experimental seizure models.
Therefore, this group of neurosteroids are mostly considered as
a novel class of antiepileptic agents. The overriding example is
ganaxolone, a representative of III generation antiepileptic drugs.
Ganaxolone (GNX, 3α-hydroxy-3β-methyl-5α-prengan-20-
one) is the 3β-methylated analog of ALLO. As the parent com-
pound,GNX is a positive allostericmodulator of GABAA receptors
and increases chloride channel permeability within the GABAA–
benzodiazepine receptor–chloride ionophore complex (Carter
et al., 1997; Monaghan et al., 1997; Nohria and Giller, 2007). The
neurosteroid exhibited effectiveness in a broad range of animal
models of epilepsy, including convulsions induced by pentylenete-
trazole, bicuculline, ﬂuorothyl, cocaine, aminophylline, as well as
in pentylenetetrazole kindling, amygdala kindling, and 6Hz elec-
trical stimulation (Gasior et al., 2000; Ungard et al., 2000; Reddy
and Rogawski, 2000a,b; Kaminski et al., 2004). Powerful anti-
seizure effects of GNX in the amygdala-kindled model in mice
strongly support the utility of this substance in the treatment of
temporal lobe epilepsy (Reddy and Rogawski, 2010). However,
most data on this neurosteroid was obtained in preclinical models
of catamenial epilepsy. According to Reddy and Rogawski (2009),
GNX treatment (7mg/kg, sc) signiﬁcantly reduced the frequency
of spontaneous seizures in rats. These results raise the possibil-
ity that GNX might provide a speciﬁc treatment for catamenial
epilepsy in humans. On the other hand, this ALLO analog proved
to be ineffective against NMDA- and strychnine-induced seizures
in mice (Carter et al., 1997; Gasior et al., 1997). In clinical studies,
GNXwas shown to bewell tolerated in adults and children. In early
phase II studies, GNX was found to be effective in adult patients
with partial-onset seizures and in epileptic childrenwith history of
infantile spasms.Currently, further investigations are conducted in
infants with newly diagnosed infantile spasms, women with cata-
menial epilepsy, and adults with refractory partial-onset seizures
(Rogawski and Reddy, 2004).
It was recently reported that the pretreatment with a new
synthesized analog of ALLO, 3α-hydroxy-21,22-oxido-21-homo-
5α-pregnan-20-on (HOHP), suppressed generalized tonic–clonic
seizures in pentylenetetrazol-induced seizures inmice, and efﬁcacy
of this analog resembled that of GNX (Mareš et al., 2010).
Two synthetic neurosteroids, minaxolone (2β,3α,5α,11α)-
11-(dimethylamino)-2-(ethoxy-3-hydroxypregnan-20-one), and
alfaxalone (5α-pregnan-3α-ol-11,20-dione) seem to be effective
positive allosteric modulators of the α1 glycine receptor (Maksay
and Biro, 2002; Weir et al., 2004). Both analogs proved efﬁcacy
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against pentylenetetrazole- and bicuculline-induced convulsions
in animals. Alphaxalone showed, moreover, a moderate anti-
convulsive activity in the rat model of kindling and maximal
electroshock in mice (Rogawski and Reddy, 2004).
Another synthetic neurosteroid,Co2-1068 (3β-(4acetylphenyl)
ethynyl-3α,21-dihydroxy-5β-20-one-21-hemisuccinate) was re-
ported to be effective against pentylenetetrazole-, NMDA-, and
cocaine-induced seizures in mice (Gasior et al., 1997).
So far,onlyﬂuasterone (DHEF),a novelDHEAanalog,was con-
sidered as a candidate for a drug used in the treatment of TBI in
humans. This steroid was reported to improve functional recov-
ery in the rat TBI model. Possible DHEF mechanisms of action
are still unclear and discussed. According to Malik et al. (2003),
this neurosteroid markedly inhibited synthesis of prostaglandin
(PGE2) and interleukin-1βa-induced cyclooxygenase-2 (COX2)
in cultures of rat mesangial, but not cortical or hippocampal cells
(Malik et al., 2003) (Table 1).
CONCLUSION
Neurosteroids may exhibit neuroprotective effects in both central
and peripheral nervous system. These natural and synthetic com-
pounds attenuate the excitotoxicity, brain edema, inﬂammatory
processes, oxidative stress, and neural degeneration. Additionally,
neurosteroids accelerate and improve regeneration and myelina-
tion. Promising results of preclinical studies directed scientist
attention toward possible proﬁts of neurosteroid treatment in
a wide range of diseases, especially the brain and spinal cord
injury, stroke, Parkinson’s and Alzheimer’s diseases, or epilepsy.
Unfortunately, therapeutic application of natural neurosteroids
was signiﬁcantly limited by its rapid biotransformation. Only
synthetic analogs of these substances, particularly ganaxolone or
3α-ol-5β-pregnan-20-one, can be considered as potential anticon-
vulsive drugs. In fact, ganaxolone has been already classiﬁed to
antiepileptic drugs of III generation. This gives a real hope that
neurosteroids can be also used as effective neuroprotective drugs.
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